Philip Barter Articles

SPIRE-2: Cardiovascular benefit in very high risk patients

Evidence from the two cardiovascular outcomes studies with bococizumab, notably SPIRE-2, added to the buzz around FOURIER. According to PCSK9 Forum Editor Professor Philip Barter (University of New South Wales, Sydney, Australia): ‘Despite follow-up being short due to termination of the development of bococizumab, SPIRE-2…

Prof Philip Barter: How do we translate the FOURIER data to clinical practice?

PCSK9 Forum Editor Professor Philip Barter discusses FOURIER

Take home message on FOURIER

Cumulative 4-year OSLER data look good, sustained LDL lowering

In this report from OSLER (Open-Label Study of Long-term Evaluation Against LDL-C), covering the longest exposure to PCSK9 inhibitors to date, there was no decrease in the LDL cholesterol lowering response to evolocumab treatment over time, and no signal for any increase in adverse events….

Could PCSK9 inhibitors be used in FH children?

Prof Philip Barter gives his view.

Use of PCSK9 inhibitors in developing countries

Inhibitors of proprotein convertase subtilisin/kexin type-9 (PCSK9) reduce the concentration of low density lipoprotein cholesterol (LDL-C) by up to 60%, whether given as the only lipid lowering therapy or when used in people already being treated with lipid-lowering agents. The availability of PCSK9 inhibitors thus…

New cholesterol lowering drugs in news

The new PCSK9 inhibitors – drugs which reduce LDL-Cholesterol to previously manageable levels – are being reviewed by regulatory authorities worldwide. Why are they creating so much interest? Professor Philip Barter, President of the International Atherosclerosis Society comments.